Edelmann, J., Dokal, A. D., Vilventhraraja, E., Holzmann, K., Britton, D., Klymenko, T., . . . Gribben, J. G. (2021). Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. iScience.
Chicago Style CitationEdelmann, Jennifer, et al. "Rituximab and Obinutuzumab Differentially Hijack the B Cell Receptor and NOTCH1 Signaling Pathways." IScience 2021.
MLA CitationEdelmann, Jennifer, et al. "Rituximab and Obinutuzumab Differentially Hijack the B Cell Receptor and NOTCH1 Signaling Pathways." IScience 2021.
Warning: These citations may not always be 100% accurate.